MoneyShow contributor John McCamant issues short sale recommendations for three stocks in the gene-editing biotech space. The editor of The Medical Technology Stock Letter talks about recent news and repeats a Strong Buy rating for one gene-editing play on Sangamo Therapeutics.
MoneyShow contributor John McCamant issues short sale recommendations for three stocks in the gene-editing biotech space. The editor of The Medical Technology Stock Letter talks about recent news and repeats a Strong Buy rating for one gene-editing play on Sangamo Therapeutics.
Share this Article
Recommended